'How are these results even possible?': Inside Rep. Chris Collins’ painful biotech education

It was June 22, 2017, and Innate Immunotherapeutics, an Australian biotech company in which he had heavily invested, was in a crisis. The company’s in-development drug, meant to treat multiple sclerosis, turned out to be no better than placebo in a large clinical trial. The study results were confidential, emailed only to Innate’s board of directors, of which Collins was a member.